Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
ALLO
ALLO
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ALLO News
El Pollo Loco Surges After Strong Q4 Earnings Beat Estimates
Mar 13 2026
Benzinga
Allogene Therapeutics Q4 2025 Earnings Call Insights
Mar 13 2026
seekingalpha
Allogene (ALLO) Q4 2025 Earnings Call Transcript
Mar 13 2026
NASDAQ.COM
Allogene Therapeutics Q4 Earnings Beat Expectations
Mar 12 2026
seekingalpha
Allogene Therapeutics to Announce Q4 Earnings on March 12
Mar 11 2026
seekingalpha
Allogene Therapeutics Schedules Q4 2025 Earnings Call
Mar 02 2026
Newsfilter
Allogene Therapeutics to Participate in Investor Conferences
Feb 05 2026
Newsfilter
ImmunityBio Shares Triple in Three Weeks, Short-Sellers Face $500 Million Loss
Jan 21 2026
Yahoo Finance
Oncolytics Biotech Advances Immunotherapy for Accelerated Approval in Oncology
Jan 12 2026
Newsfilter
CG Oncology Accelerates Phase 3 Data Readout to First Half of 2026
Jan 09 2026
Benzinga
Cellectis Shares Under Pressure Following Allogene Arbitration Win on Tuesday
Dec 16 2025
Benzinga
Allogene Secures Global Control of Cema-Cel, Interim Analysis Set for 1H 2026
Dec 15 2025
Globenewswire
Allogene Secures Full Global Control of Cema-Cel Following Arbitration Ruling
Dec 15 2025
Newsfilter
CDTX Shares Rise Following FDA's Breakthrough Therapy Designation for CD388 in Influenza
Oct 10 2025
NASDAQ.COM
Keysight Analyst Changes Stance; Check Out the Top 5 Downgrades for Friday
Oct 10 2025
Benzinga
JP Morgan Lowers Allogene Therapeutics Rating to Underweight
Oct 10 2025
Benzinga
Show More News
